CARAMBA - Clinical Analysis & Research Applying Mass spectrometry & Bioinformatics at Akademiska

We develop analytical methods using mass spectrometry and conduct targeted analyses of low-molecular-weight compounds such as bile acids, short- and medium-chain fatty acids (SCFAs and MCFAs), and environmental contaminants. We also perform untargeted analyses, including metabolomics, lipidomics, and exposomics, and measure protein concentrations in body fluids with ultra-sensitive SIMOA technology.

We have established a state-of-the-art high-resolution mass spectrometry laboratory in close collaboration between the Department of Medical Sciences and Region Uppsala (Clinical Chemistry and Pharmacology; KKF). Since 2020, we have expanded the operation and installed a SIMOA platform for ultra-sensitive quantitative protein analyses. The operation is housed in KKF's facilities, which are shared with UU and utilize the same specialized infrastructure. Both routine diagnostic analysis and R&D are conducted on the four existing high-resolution mass spectrometers and the SIMOA platform.

Our interdisciplinary and cross-organizational platform fosters synergies and offers unique, cost-effective opportunities, particularly in translational and clinical research. Our team of experts in mass spectrometry, advanced data analysis—including artificial intelligence (AI)—and medicine is crucial for maximizing the potential of this infrastructure.

The laboratory operates within the framework of the Akademiska laboratory and shares important IT infrastructure, which enables us to deliver results on patient samples as decision support in, for example, clinical trials. We also participate in the international external quality assurance program, the German External Quality Assessment Scheme (G-EQUAS), to ensure accuracy and comparability in assessing human exposure to chemicals.

We can support you with:

• Metabolomics - non polar metabolites
• Metabolomics - polar metabolites
• Lipidomics
• Short- and medium-chain fatty acids (SCFAs and MCFAs)
• Bile acids - conjugated and unconjugated forms
• Environmental exposures (PFASs and PCBs) and the exposome
• Therapeutic drug monitoring (TDM)
• SIMOA - ultra-sensitive quantitative protein analyses